Evaluation of the antiproliferative effects of Essiac™ on in vitro and in vivo models of prostate cancer compared to paclitaxel

Nutrition and Cancer

Volumn 58, Issue 2, 2007, Pages 188-196

  Eberding, Andy ^a   Madera, Candice ^a   Xie, Sherwin ^a   Wood, Catherine A ^a   Brown, Paula N ^c   Guns, Emma S ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA INSTITUTE OF TECHNOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PLANT EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOTOXICITY; DIET; DRUG MECHANISM; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO CULTURE; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; TEA; XENOGRAFT;

MUS MUSCULUS;

EID: 34548243211     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580701328396     Document Type: Article

References (25)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, et al.: Cancer statistics, 2004. CA Cancer J Clin 54, 8-29, 2004.
2. Haenszel W and Kurihara M: Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40, 43-68, 1968.
3. Boon H, Westlake K, Stewart M, Gray R, Fleshner N, et al.: Use of complementary/alternative medicine by men diagnosed with prostate cancer: prevalence and characteristics. Urology 62, 849-853, 2003.
4. Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, et al.: Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol 22, 4810-4815, 2004.
5. Yanaghara K, Ito A, Toge T, and Numoto M: Antiproliferative effects of isoflavaones on human cancer cell lines established from the gastrointestinal tract. Cancer Res 53, 5815-5821, 1993.
6. Umehara K, Nakamura H, Miyase T, Kuroyanagi M, and Ueno A: Studies on differentiation inducers. VI. Lignan derivatives from Arctium Fructus. Chem Pharm Bull 44, 2300-2304, 1996.
7. Belkin M and Fitzgerald D: Tumor damaging capacity of plant materials 1. Plants used as cathartics. J Natl Cancer Inst 13, 139-155, 1952.
8. Kubo I, Murai Y, Soedro I, Soentarno S, and Satrodiharojo S: Cytotoxic anthroquinones from Rheum Palmatum. Phytochemistry 31, 1063-1065, 1992.
9. Morita H, Umeda M, Masuda T, and Ueno Y: Cytotoxic and mutagenic effects of emodin on cultured mouse carcinoma FM3A cells. Mutat Res 204, 329-332, 1988.
10. Tamayo C, Richardson MA, Diamond S, and Skoda I: The chemistry and biological activity of herbs used in Flor-Essence herbal tonic and Essiac™ . Phytother Res 14, 1-14, 2000.
11. Canadian Breast Cancer Research Initiative. Essiac™: An Information Package. Toronto, Ontario, Canada: CBCRI, 1996.
12. Health and Welfare Canada. Essiac™ - An Ineffective Cancer Treatment. Vanier, Ontario: Health and Welfare Canada, Health Protection Branch, 1989.
13. Cheung S, Lim KT, and Tai J: Antioxidant and anti-inflammatory properties of Essiac™ and Flor-Essence. Oncol Rep 14, 1345-1350, 2005.
14. Leonard SS, Keil D, Mehlman T, Proper S, Shi X, et al.: Essiac™ tea: scavenging of reactive oxygen species and effects on DNA damage. J Ethnopharmacol 103(2), 288-296, 2006.
15. Ottenweller J, Putt K, Blumenthal EJ, Dhawale S, and Dhawale SW: Inhibition of prostate cancer-cell proliferation by Essiac™. J Altern Complement Med 10, 687-691, 2004.
16. Kulp KS, Montgomery JL, Nelson DO, Cutter B, Latham ER, et al.: Essiac™ and Flor-Essence herbal tonics stimulate the in vitro growth of human breast cancer cells. Breast Cancer Res Treat 16, 16, 2006.
17. Al-Sukhni W, Grunbaum A, and Fleshner N: Remission of hormone-refractory prostate cancer attributed to Essiac™. Can J Urol 12, 2841-2842, 2005.
18. Richardson MA, Sanders T, Palmer JL, Greisinger A, and Singletary SE: Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18, 2505-2514, 2000.
19. Navone NM, Logothetis CJ, von Eschenbach AC, and Troncoso P: Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev 17, 361-371, 1998.
20. Schiff PB, Fant J, and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277, 665-667, 1979.
21. Parness J and Horwitz SB: Taxol binds to polymerized tubulin in vitro. J Cell Biol 91, 479-487, 1981.
22. Leung SY, Jackson J, Miyake H, Burt H, and Gleave ME: Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. Prostate 44, 156-163, 2000.
23. Stepensky D, Kleinberg L, and Hoffman A: Bone as an effect compartment : models for uptake and release of drugs. Clin Pharmacokinet 42, 863-881, 2003.
24. Bruno S and Darzynkiewicz Z: Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif 25, 31-40, 1992.
25. Takasaki Y, Deng JS, and Tan EM: A nuclear antigen associated with cell proliferation and blast transformation. J Exp Med 154, 1899-1909, 1981.